...demic groups (ten large clinical trialsites), 6 EFPIA companies with extensive experience in the use of blood-based biomarkers in clinical trials, 5 SMEs with unique technologies for CTC isolation (Vycap, Leukocare, Gilupi) or for creation of databases, analysis of complex molecular information and data management (Alacris, TATAA) and two non-profit organizations (IBBL, a Biobank with extensive ex ...